Li Watsek
Stock Analyst at Cantor Fitzgerald
(2.49)
# 2,200
Out of 5,182 analysts
81
Total ratings
54.22%
Success rate
-1.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Downgrades: Neutral | n/a | $2.85 | - | 3 | Apr 13, 2026 | |
| ZLAB Zai Lab | Maintains: Overweight | $55 → $37 | $21.88 | +69.10% | 2 | Feb 27, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | n/a | $36.69 | - | 1 | Feb 24, 2026 | |
| AVBP ArriVent BioPharma | Initiates: Overweight | n/a | $31.00 | - | 1 | Dec 23, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | n/a | $5.21 | - | 1 | Dec 3, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $203 → $254 | $225.12 | +12.83% | 20 | Oct 13, 2025 | |
| CNTX Context Therapeutics | Initiates: Overweight | n/a | $2.32 | - | 1 | Oct 2, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $30.70 | - | 3 | Sep 9, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $9.27 | - | 11 | Jun 26, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.89 | - | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $5.26 | - | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.42 | - | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.59 | - | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $25.13 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.85 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.61 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.02 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $4.64 | -35.34% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.32 | +278.79% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.98 | +1,175.17% | 1 | Aug 12, 2022 |
Replimune Group
Apr 13, 2026
Downgrades: Neutral
Price Target: n/a
Current: $2.85
Upside: -
Zai Lab
Feb 27, 2026
Maintains: Overweight
Price Target: $55 → $37
Current: $21.88
Upside: +69.10%
Tyra Biosciences
Feb 24, 2026
Initiates: Overweight
Price Target: n/a
Current: $36.69
Upside: -
ArriVent BioPharma
Dec 23, 2025
Initiates: Overweight
Price Target: n/a
Current: $31.00
Upside: -
Compass Therapeutics
Dec 3, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.21
Upside: -
Ascendis Pharma
Oct 13, 2025
Maintains: Overweight
Price Target: $203 → $254
Current: $225.12
Upside: +12.83%
Context Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $2.32
Upside: -
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: n/a
Current: $30.70
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.27
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.89
Upside: -
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.26
Upside: -
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.42
Upside: -
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.59
Upside: -
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $25.13
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.85
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.61
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.02
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $4.64
Upside: -35.34%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.32
Upside: +278.79%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.98
Upside: +1,175.17%